The PAS submission is a positive regulatory milestone but approval is not guaranteed and is 6-12 months away. Monitor for FDA acceptance of the filing and any updates on review timeline. The stock may see a modest positive reaction on the news, but the event is not a final approval catalyst.
Price Chart
Executive Summary
Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI (hydrocortisone) oral solution's label to include pediatric patients under age 5. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and a potential approval is expected in the first half of 2027. This expands the addressable market for the only FDA-approved oral liquid hydrocortisone, currently approved for ages 5+.
Key Facts
- Eton submitted a PAS to the FDA for KHINDIVI label expansion to include pediatric patients under 5 years old.
- New formulation showed bioequivalence to ALKINDI SPRINKLE oral granules.
- Potential approval expected in first half of 2027.
- KHINDIVI is the only FDA-approved oral solution of hydrocortisone, currently approved for ages 5 and older.
- Eton estimates approximately 10,000 pediatric adrenal insufficiency patients in the U.S.
Financial Impact
Potential label expansion to younger pediatric patients, expanding addressable market from ~10,000 patients; no financial figures provided.
Risk Factors
- FDA may reject or require additional data for the label expansion.
- Competition from other hydrocortisone formulations (e.g., compounded liquids, ALKINDI SPRINKLE).
- Approval timeline may extend beyond first half 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3335064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 8-K | $52.88 | awaiting T+60 | — | $50.42 (−4.65%) |
Oct 6, 2026 20d ago | 144 | $54.88 | awaiting T+60 | — | $50.42 (−8.13%) |
Sep 28, 2026 29d ago | 8-K | $59.18 | awaiting T+60 | — | $50.42 (−14.80%) |
Aug 31, 2026 8w ago | Insider Cluster | $60.43 | awaiting T+60 | — | $50.42 (−16.56%) |
Aug 28, 2026 8w ago | Insider Cluster | $60.44 | awaiting T+60 | — | $50.42 (−16.58%) |
Aug 24, 2026 9w ago | Insider Cluster | $63.05 | awaiting T+60 | — | $50.42 (+20.03%) |
Aug 19, 2026 9w ago | 144 | $61.48 | awaiting T+60 | — | $50.42 (+17.99%) |
Aug 5, 2026 11w ago | 8-K | $45.97 | awaiting T+60 | — | $50.42 (+9.68%) |
Aug 5, 2026 11w ago | Press Release | $45.97 | awaiting T+60 | — | $50.42 (+9.68%) |
Aug 4, 2026 12w ago | 8-K | $45.83 | awaiting T+60 | — | $50.42 (+10.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers